End-of-day quote
Other stock markets
|
||
- GBX | - |
05-08 | UBS raises Centrica to 'buy' from 'neutral | AN |
05-07 | AstraZeneca target raised; Antofagasta lowered | AN |
Sales 2024 * | 3.89B 4.98B 389B | Sales 2025 * | 4.27B 5.47B 427B | Capitalization | 3.94B 5.05B 394B |
---|---|---|---|---|---|
Net income 2024 * | 466M 597M 46.6B | Net income 2025 * | 500M 640M 50B | EV / Sales 2024 * | 1.14 x |
Net Debt 2024 * | 513M 657M 51.3B | Net Debt 2025 * | 513M 657M 51.3B | EV / Sales 2025 * | 1.04 x |
P/E ratio 2024 * |
8.44
x | P/E ratio 2025 * |
7.75
x | Employees | - |
Yield 2024 * |
2.8% | Yield 2025 * |
3.1% | Free-Float | 97.46% |
Latest transcript on Hiscox Ltd
Managers | Title | Age | Since |
---|---|---|---|
Hamayou Hussain
CEO | Chief Executive Officer | 51 | 21/04/16 |
Paul Cooper
DFI | Director of Finance/CFO | 52 | 11/05/22 |
Stéphane Flaquet
COO | Chief Operating Officer | - | 28/02/10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 60 | 15/11/17 | |
Anne MacDonald
BRD | Director/Board Member | 68 | 19/05/15 |
Colin Keogh
BRD | Director/Board Member | 69 | 18/11/15 |
1st Jan change | Capi. | |
---|---|---|
+59.79% | 67.71B | |
+15.60% | 52.31B | |
+10.42% | 49.39B | |
+17.25% | 44.21B | |
+36.93% | 38.38B | |
+83.10% | 33.19B | |
+11.44% | 29.8B | |
+25.26% | 25.44B | |
+0.73% | 21.46B |